首页 > 最新文献

Scandinavian Journal of Surgery最新文献

英文 中文
Practice patterns in diagnostics, staging, and management strategies of gallbladder cancer among Nordic tertiary centers. 北欧三级中心胆囊癌诊断、分期和治疗策略的实践模式。
IF 2.4 3区 医学 Q1 SURGERY Pub Date : 2023-09-01 DOI: 10.1177/14574969231181228
Sini Takala, Kristoffer Lassen, Kjetil Søreide, Ernesto Sparrelid, Jon-Helge Angelsen, Erling A Bringeland, Malin S Eilard, Oskar Hemmingsson, Bengt Isaksson, Heikki Karjula, Jukka-Pekka Lammi, Peter N Larsen, Maija Lavonius, Gert Lindell, Frank V Mortensen, Kim Mortensen, Arno Nordin, Torsten Pless, Per Sandström, Oddvar Sandvik, Yrjö Vaalavuo, Christina Villard, Ville Sallinen

Background and objective: Gallbladder cancer (GBC) is a rare malignancy in the Nordic countries and no common Nordic treatment guidelines exist. This study aimed to characterize the current diagnostic and treatment strategies in the Nordic countries and disclose differences in these strategies.

Methods: This was a survey study with a cross-sectional questionnaire of all 19 university hospitals providing curative-intent surgery for GBC in Sweden, Norway, Denmark, and Finland.

Results: In all Nordic countries except Sweden, neoadjuvant/downstaging chemotherapy was used in GBC patients. In T1b and T2, majority of the centers (15-18/19) performed extended cholecystectomy. In T3, majority of the centers (13/19) performed cholecystectomy with resection of segments 4b and 5. In T4, majority of the centers (12-14/19) chose palliative/oncological care. The centers in Sweden extended lymphadenectomy beyond the hepatoduodenal ligament, whereas all other Nordic centers usually limited lymphadenectomy to the hepatoduodenal ligament. All Nordic centers except those in Norway used adjuvant chemotherapy routinely for GBC. There were no major differences between the Nordic centers in diagnostics and follow-up.

Conclusions: The surgical and oncological treatment strategies of GBC vary considerably between the Nordic centers and countries.

背景和目的:胆囊癌(GBC)在北欧国家是一种罕见的恶性肿瘤,没有统一的北欧治疗指南。本研究旨在描述北欧国家目前的诊断和治疗策略,并揭示这些策略的差异。方法:这是一项调查研究,采用横断面问卷调查瑞典、挪威、丹麦和芬兰所有19所大学医院为GBC提供治疗目的手术。结果:在除瑞典外的所有北欧国家,GBC患者均采用新辅助/降期化疗。在T1b和T2中,大多数中心(15-18/19)行扩大胆囊切除术。在T3,大多数中心(13/19)行胆囊切除术,切除4b和5节段。在T4期,大多数中心(12-14/19)选择姑息治疗/肿瘤治疗。瑞典的中心将淋巴结切除术扩展到肝十二指肠韧带以外,而所有其他北欧中心通常将淋巴结切除术限制在肝十二指肠韧带。除挪威外,所有北欧中心常规使用辅助化疗治疗GBC。北欧中心在诊断和随访方面没有重大差异。结论:GBC的手术和肿瘤治疗策略在北欧中心和国家之间差异很大。
{"title":"Practice patterns in diagnostics, staging, and management strategies of gallbladder cancer among Nordic tertiary centers.","authors":"Sini Takala,&nbsp;Kristoffer Lassen,&nbsp;Kjetil Søreide,&nbsp;Ernesto Sparrelid,&nbsp;Jon-Helge Angelsen,&nbsp;Erling A Bringeland,&nbsp;Malin S Eilard,&nbsp;Oskar Hemmingsson,&nbsp;Bengt Isaksson,&nbsp;Heikki Karjula,&nbsp;Jukka-Pekka Lammi,&nbsp;Peter N Larsen,&nbsp;Maija Lavonius,&nbsp;Gert Lindell,&nbsp;Frank V Mortensen,&nbsp;Kim Mortensen,&nbsp;Arno Nordin,&nbsp;Torsten Pless,&nbsp;Per Sandström,&nbsp;Oddvar Sandvik,&nbsp;Yrjö Vaalavuo,&nbsp;Christina Villard,&nbsp;Ville Sallinen","doi":"10.1177/14574969231181228","DOIUrl":"https://doi.org/10.1177/14574969231181228","url":null,"abstract":"<p><strong>Background and objective: </strong>Gallbladder cancer (GBC) is a rare malignancy in the Nordic countries and no common Nordic treatment guidelines exist. This study aimed to characterize the current diagnostic and treatment strategies in the Nordic countries and disclose differences in these strategies.</p><p><strong>Methods: </strong>This was a survey study with a cross-sectional questionnaire of all 19 university hospitals providing curative-intent surgery for GBC in Sweden, Norway, Denmark, and Finland.</p><p><strong>Results: </strong>In all Nordic countries except Sweden, neoadjuvant/downstaging chemotherapy was used in GBC patients. In T1b and T2, majority of the centers (15-18/19) performed extended cholecystectomy. In T3, majority of the centers (13/19) performed cholecystectomy with resection of segments 4b and 5. In T4, majority of the centers (12-14/19) chose palliative/oncological care. The centers in Sweden extended lymphadenectomy beyond the hepatoduodenal ligament, whereas all other Nordic centers usually limited lymphadenectomy to the hepatoduodenal ligament. All Nordic centers except those in Norway used adjuvant chemotherapy routinely for GBC. There were no major differences between the Nordic centers in diagnostics and follow-up.</p><p><strong>Conclusions: </strong>The surgical and oncological treatment strategies of GBC vary considerably between the Nordic centers and countries.</p>","PeriodicalId":49566,"journal":{"name":"Scandinavian Journal of Surgery","volume":"112 3","pages":"147-156"},"PeriodicalIF":2.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10098277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pelvic bone sarcomas, prognostic factors, and treatment: A narrative review of the literature. 骨盆骨肉瘤,预后因素和治疗:文献综述。
IF 2.4 3区 医学 Q1 SURGERY Pub Date : 2023-09-01 DOI: 10.1177/14574969231181504
Minna K Laitinen, Michael C Parry, Guy V Morris, Lee M Jeys

Primary sarcomas of bone are rare malignant mesenchymal tumors. The most common bone sarcomas are osteosarcoma, Ewing's sarcoma, and chondrosarcoma. The prognosis has improved over the years, but bone sarcomas are still life-threatening tumors that need a multidisciplinary approach for diagnosis and treatment. Bone sarcomas arising in the pelvis present a unique challenge to orthopedic oncologists due to the absence of natural anatomical barriers, the close proximity of vital neurovascular structures, and the high mechanical demands placed on any pelvic reconstruction following the excision of the tumor. While radiotherapy has an important role especially in Ewing's sarcoma and chemotherapy for both Ewing's sarcoma and osteosarcoma, surgery remains the main choice of treatment for all three entities. While external hemipelvectomy has remained one option, the main aim of surgery is limb salvage. After complete tumor resection, the bone defect needs to be reconstructed. Possibilities to reconstruct the defect include prosthetic or biological reconstruction. The method of reconstruction is dependent on the location of tumor and the surgery required for its removal. The aim of this article is to give an insight into pelvic bone sarcomas, their oncological and surgical outcomes, and the options for treatment based on the authors' experiences.

原发性骨肉瘤是一种罕见的恶性间质肿瘤。最常见的骨肉瘤是骨原性肉瘤、尤文氏肉瘤和软骨肉瘤。多年来,预后有所改善,但骨肉瘤仍然是危及生命的肿瘤,需要多学科的诊断和治疗方法。骨盆骨肉瘤对骨科肿瘤学家来说是一个独特的挑战,因为它缺乏天然的解剖屏障,靠近重要的神经血管结构,并且在切除肿瘤后对任何骨盆重建都有很高的机械要求。虽然放疗在尤文氏肉瘤中起着重要的作用,而化疗在尤文氏肉瘤和骨原性肉瘤中都起着重要的作用,但手术仍然是这三种肿瘤的主要治疗选择。虽然外半骨盆切除术仍然是一种选择,但手术的主要目的是保留肢体。肿瘤完全切除后,需要重建骨缺损。修复缺损的方法包括假体或生物修复。重建的方法取决于肿瘤的位置和切除所需的手术。本文的目的是根据作者的经验,深入了解骨盆骨肉瘤,其肿瘤和手术结果,以及治疗方案。
{"title":"Pelvic bone sarcomas, prognostic factors, and treatment: A narrative review of the literature.","authors":"Minna K Laitinen,&nbsp;Michael C Parry,&nbsp;Guy V Morris,&nbsp;Lee M Jeys","doi":"10.1177/14574969231181504","DOIUrl":"https://doi.org/10.1177/14574969231181504","url":null,"abstract":"<p><p>Primary sarcomas of bone are rare malignant mesenchymal tumors. The most common bone sarcomas are osteosarcoma, Ewing's sarcoma, and chondrosarcoma. The prognosis has improved over the years, but bone sarcomas are still life-threatening tumors that need a multidisciplinary approach for diagnosis and treatment. Bone sarcomas arising in the pelvis present a unique challenge to orthopedic oncologists due to the absence of natural anatomical barriers, the close proximity of vital neurovascular structures, and the high mechanical demands placed on any pelvic reconstruction following the excision of the tumor. While radiotherapy has an important role especially in Ewing's sarcoma and chemotherapy for both Ewing's sarcoma and osteosarcoma, surgery remains the main choice of treatment for all three entities. While external hemipelvectomy has remained one option, the main aim of surgery is limb salvage. After complete tumor resection, the bone defect needs to be reconstructed. Possibilities to reconstruct the defect include prosthetic or biological reconstruction. The method of reconstruction is dependent on the location of tumor and the surgery required for its removal. The aim of this article is to give an insight into pelvic bone sarcomas, their oncological and surgical outcomes, and the options for treatment based on the authors' experiences.</p>","PeriodicalId":49566,"journal":{"name":"Scandinavian Journal of Surgery","volume":"112 3","pages":"206-215"},"PeriodicalIF":2.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10101961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Learning curves in robot-assisted minimally invasive liver surgery at a high-volume center in Denmark: Report of the first 100 patients and review of literature. 丹麦一个大容量中心机器人辅助微创肝脏手术的学习曲线:前100名患者的报告和文献综述。
IF 2.4 3区 医学 Q1 SURGERY Pub Date : 2023-09-01 DOI: 10.1177/14574969221146003
Daisuke Fukumori, Christoph Tschuor, Luit Penninga, Jens Hillingsø, Lars Bo Svendsen, Peter Nørgaard Larsen

Background and objective: Minimally invasive liver surgery is evolving worldwide, and robot-assisted liver surgery (RLS) can deliver obvious benefits for patients. However, so far no large case series have documented the learning curve for RLS.

Methods: We conducted a retrospective study for robotic liver surgery (RLS) from June 2019 to June 2022 where 100 patients underwent RLS by the same surgical team. Patients' variables, short-term follow-up, and the learning curve were analyzed. A review of the literature describing the learning curve in RLS was also conducted.

Results: Mean patient age was 63.1 years. The median operating time was 246 min and median estimated blood loss was 100 mL. Thirty-two patients underwent subsegmentectomy, 18 monosegmentectomies, 25 bisegmentectomies, and 25 major hepatectomies. One patient (1.0%) required conversion to open surgery. Five patients (5%) experienced postoperative major complications, and no mortalities occurred. Median length of hospital stay was 3 days. R0 resection was achieved in 93.4% of the malignant cases. The learning curve consisted of three stages; there were no significant differences in operative time, transfusion rate, or complication rate among the three groups. Postoperative complications were similar in each group despite an increase in surgical difficulty scores. The learning effect was highlighted by significantly shorter hospital stays in cohorts I, II, and III, respectively. The included systematic review suggested that the learning curve for RLS is similar to, or shorter, than that of laparoscopic liver surgery.

Conclusions: In our experience, RLS has achieved good clinical results, albeit in the short term. Standardization of training leads to increasing proficiency in RLS with reduced blood loss and low complication rates even in more advanced liver resections. Our study suggests that a minimum of 30 low-to-moderate difficulty robotic procedures should be performed before proceeding to more difficult resections.

背景与目的:微创肝脏手术在世界范围内不断发展,机器人辅助肝脏手术(RLS)可以为患者带来明显的好处。然而,到目前为止,还没有大型病例系列记录了RLS的学习曲线。方法:我们对2019年6月至2022年6月期间同一外科团队进行的100例机器人肝脏手术(RLS)患者进行了回顾性研究。分析患者变量、短期随访及学习曲线。我们还回顾了描述RLS学习曲线的文献。结果:患者平均年龄63.1岁。中位手术时间为246分钟,中位估计失血量为100毫升。32例患者接受了亚节段切除术,18例接受了单节段切除术,25例接受了双节段切除术,25例接受了肝大部切除术。1例(1.0%)患者需要转开手术。5例(5%)患者出现术后主要并发症,无死亡。住院时间中位数为3天。93.4%的恶性肿瘤达到R0切除。学习曲线包括三个阶段;三组患者在手术时间、输血率、并发症发生率等方面均无显著差异。尽管手术难度评分增加,但两组术后并发症相似。在队列I、II和III中,学习效果分别被显著缩短的住院时间所突出。纳入的系统评价表明,RLS的学习曲线与腹腔镜肝脏手术相似或更短。结论:根据我们的经验,RLS取得了良好的临床效果,尽管是短期的。规范化的培训提高了对RLS的熟练程度,减少了出血量,甚至在更晚期的肝脏切除术中也降低了并发症发生率。我们的研究表明,在进行更困难的切除之前,至少应该进行30次低至中等难度的机器人手术。
{"title":"Learning curves in robot-assisted minimally invasive liver surgery at a high-volume center in Denmark: Report of the first 100 patients and review of literature.","authors":"Daisuke Fukumori,&nbsp;Christoph Tschuor,&nbsp;Luit Penninga,&nbsp;Jens Hillingsø,&nbsp;Lars Bo Svendsen,&nbsp;Peter Nørgaard Larsen","doi":"10.1177/14574969221146003","DOIUrl":"https://doi.org/10.1177/14574969221146003","url":null,"abstract":"<p><strong>Background and objective: </strong>Minimally invasive liver surgery is evolving worldwide, and robot-assisted liver surgery (RLS) can deliver obvious benefits for patients. However, so far no large case series have documented the learning curve for RLS.</p><p><strong>Methods: </strong>We conducted a retrospective study for robotic liver surgery (RLS) from June 2019 to June 2022 where 100 patients underwent RLS by the same surgical team. Patients' variables, short-term follow-up, and the learning curve were analyzed. A review of the literature describing the learning curve in RLS was also conducted.</p><p><strong>Results: </strong>Mean patient age was 63.1 years. The median operating time was 246 min and median estimated blood loss was 100 mL. Thirty-two patients underwent subsegmentectomy, 18 monosegmentectomies, 25 bisegmentectomies, and 25 major hepatectomies. One patient (1.0%) required conversion to open surgery. Five patients (5%) experienced postoperative major complications, and no mortalities occurred. Median length of hospital stay was 3 days. R0 resection was achieved in 93.4% of the malignant cases. The learning curve consisted of three stages; there were no significant differences in operative time, transfusion rate, or complication rate among the three groups. Postoperative complications were similar in each group despite an increase in surgical difficulty scores. The learning effect was highlighted by significantly shorter hospital stays in cohorts I, II, and III, respectively. The included systematic review suggested that the learning curve for RLS is similar to, or shorter, than that of laparoscopic liver surgery.</p><p><strong>Conclusions: </strong>In our experience, RLS has achieved good clinical results, albeit in the short term. Standardization of training leads to increasing proficiency in RLS with reduced blood loss and low complication rates even in more advanced liver resections. Our study suggests that a minimum of 30 low-to-moderate difficulty robotic procedures should be performed before proceeding to more difficult resections.</p>","PeriodicalId":49566,"journal":{"name":"Scandinavian Journal of Surgery","volume":"112 3","pages":"164-172"},"PeriodicalIF":2.4,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10098440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
A role for pelvic sentinel lymph nodes in lower extremity melanoma? 盆腔前哨淋巴结在下肢黑色素瘤中的作用?
IF 2.4 3区 医学 Q1 SURGERY Pub Date : 2023-06-01 DOI: 10.1177/14574969221149968
Juulia Laakkonen, Outi Kaarela, Tomi Tervala, Henrik Nuutinen

Background and objective: Consensus on management of pelvic sentinel lymph nodes (PSLNs) has not been reached and thus the extent of sentinel lymph node biopsy (SLNB) of the groin in melanoma patients varies among centers and surgeons. Lymphatic drainage to PSLNs is often identified in, but the diagnostic and clinical relevance of PSLNs has been debated. Our aim was to determine if the presence of PSLNs affected recurrence or survival rates in patients with melanoma in the lower extremities.

Methods: This retrospective study consisted of 702 patients with cutaneous melanoma operated between 2005 and 2018. Of these, 134 patients with melanoma in the lower extremities were included in the study. Images of lymphoscintigraphy and SPECT-CT studies were thoroughly observed together with surgery reports to define the status of SLNs.

Results: Overall, 85 of 134 patients went through SLNB and 28 of them had PSLN identified. Two had their PSLN removed, which led 26 patients with PSLN to be compared to the 57 who did not have PSLN identified. We did not find statistically significant differences in overall recurrence (26.9% versus 28.0%, p = 1.00), regional nodal recurrence (11.5% versus 15.8%, p = 0.67), local or in-transit recurrence (19.2% versus 8.8%, p = 0.17), or distant recurrence rates (15.4% versus 19.3%, p = 0.66). Disease-free survival did not differ between the groups (median 23.0 (IQR 15.0-39.0) versus 19.0 (IQR 10.3-61.8) months, p = 0.82). Likewise, there was no statistically significant difference in melanoma-specific 5-year survival (78.6% versus 87.2%, p = 0.42).

Conclusions: We did not find more frequent recurrence, shorter disease-free survival, or poorer melanoma-specific survival in patients with drainage to PSLN. Our findings strengthen the evidence that PSLNs should not be routinely biopsied if they are not the first-tier nodes.

背景与目的:关于盆腔前哨淋巴结(psln)的处理尚未达成共识,因此各中心和外科医生对黑色素瘤患者腹股沟前哨淋巴结活检(SLNB)的程度有所不同。淋巴引流到psln经常被发现,但psln的诊断和临床相关性一直存在争议。我们的目的是确定psln的存在是否影响下肢黑色素瘤患者的复发率或生存率。方法:本回顾性研究包括2005年至2018年期间手术的702例皮肤黑色素瘤患者。其中,134名下肢黑色素瘤患者被纳入研究。仔细观察淋巴显像和SPECT-CT图像,并结合手术报告来确定sln的状态。结果:134例患者中85例行SLNB,其中28例确诊为PSLN。两名患者的PSLN被切除,这使得26名患有PSLN的患者与57名未发现PSLN的患者进行了比较。我们没有发现总体复发率(26.9%比28.0%,p = 1.00)、局部淋巴结复发率(11.5%比15.8%,p = 0.67)、局部或中转复发率(19.2%比8.8%,p = 0.17)或远处复发率(15.4%比19.3%,p = 0.66)的统计学差异。两组无病生存期无差异(中位23.0个月(IQR 15.0-39.0) vs中位19.0个月(IQR 10.3-61.8), p = 0.82)。同样,黑色素瘤特异性5年生存率无统计学差异(78.6% vs 87.2%, p = 0.42)。结论:我们没有发现PSLN引流患者更频繁的复发、更短的无病生存期或更差的黑色素瘤特异性生存期。我们的发现加强了psln如果不是一级淋巴结就不应该常规活检的证据。
{"title":"A role for pelvic sentinel lymph nodes in lower extremity melanoma?","authors":"Juulia Laakkonen,&nbsp;Outi Kaarela,&nbsp;Tomi Tervala,&nbsp;Henrik Nuutinen","doi":"10.1177/14574969221149968","DOIUrl":"https://doi.org/10.1177/14574969221149968","url":null,"abstract":"<p><strong>Background and objective: </strong>Consensus on management of pelvic sentinel lymph nodes (PSLNs) has not been reached and thus the extent of sentinel lymph node biopsy (SLNB) of the groin in melanoma patients varies among centers and surgeons. Lymphatic drainage to PSLNs is often identified in, but the diagnostic and clinical relevance of PSLNs has been debated. Our aim was to determine if the presence of PSLNs affected recurrence or survival rates in patients with melanoma in the lower extremities.</p><p><strong>Methods: </strong>This retrospective study consisted of 702 patients with cutaneous melanoma operated between 2005 and 2018. Of these, 134 patients with melanoma in the lower extremities were included in the study. Images of lymphoscintigraphy and SPECT-CT studies were thoroughly observed together with surgery reports to define the status of SLNs.</p><p><strong>Results: </strong>Overall, 85 of 134 patients went through SLNB and 28 of them had PSLN identified. Two had their PSLN removed, which led 26 patients with PSLN to be compared to the 57 who did not have PSLN identified. We did not find statistically significant differences in overall recurrence (26.9% versus 28.0%, <i>p</i> = 1.00), regional nodal recurrence (11.5% versus 15.8%, <i>p</i> = 0.67), local or in-transit recurrence (19.2% versus 8.8%, <i>p</i> = 0.17), or distant recurrence rates (15.4% versus 19.3%, <i>p</i> = 0.66). Disease-free survival did not differ between the groups (median 23.0 (IQR 15.0-39.0) versus 19.0 (IQR 10.3-61.8) months, <i>p</i> = 0.82). Likewise, there was no statistically significant difference in melanoma-specific 5-year survival (78.6% versus 87.2%, <i>p</i> = 0.42).</p><p><strong>Conclusions: </strong>We did not find more frequent recurrence, shorter disease-free survival, or poorer melanoma-specific survival in patients with drainage to PSLN. Our findings strengthen the evidence that PSLNs should not be routinely biopsied if they are not the first-tier nodes.</p>","PeriodicalId":49566,"journal":{"name":"Scandinavian Journal of Surgery","volume":"112 2","pages":"91-97"},"PeriodicalIF":2.4,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10053421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radio frequency ablation of dysplastic Barrett's esophagus: Outcomes of a single-center registry. 射频消融治疗发育不良的Barrett食管:单中心登记的结果。
IF 2.4 3区 医学 Q1 SURGERY Pub Date : 2023-06-01 DOI: 10.1177/14574969231151378
Molly Mathiesen, Jakob Holm, Morten Thorsteinsson

Background and objective: Barrett's esophagus (BE) is associated with an increased risk of esophageal adenocarcinoma. The use of radio frequency ablation (RFA) for complete eradication of BE with confirmed low-grade dysplasia (LGD) or high-grade dysplasia (HGD) has been promising in multicenter trials. Our aim was to evaluate the safety and efficacy outcomes associated with RFA for patients with BE and LGD/HGD in a single-center setting.

Methods: This was a retrospective single-center study conducted at Department of Surgery and Transplantation, Rigshospitalet, Denmark. Data were collected from all patients who had undergone RFA for LGD or HGD from January 2014 to December 2018. Effectiveness outcomes were based on histology: complete eradication of dysplasia (CE-D), defined as all esophageal biopsies being negative for dysplasia at the last biopsy session, and complete eradication of intestinal metaplasia (CE-IM) defined as esophageal biopsies being without intestinal metaplasia. Safety outcomes were based on the proportion of complications to the RFA treatment.

Results: A total of 107 patients were identified during the follow-up period (75% men, median age = 65 years); 83% had LGD and 17% had HGD. The median follow-up was 25 months. After the last RFA treatment, CE-D was achieved in 89%. CE-D and CE-IM were achieved in 60%. Complications occurred in 6.5% of the patients.

Conclusions: In patients with BE and confirmed LGD or HGD, RFA was associated with a high rate of CE-D and a low risk of complications. The observed safety and efficacy outcomes were comparable with those previously reported in multicenter trials, showing that the Danish treatment of BE with LGD and HGD is comparable with those of larger European expert centers.

背景和目的:巴雷特食管(BE)与食管腺癌风险增加相关。在多中心试验中,使用射频消融(RFA)完全根除确诊为低级别发育不良(LGD)或高级别发育不良(HGD)的BE是有希望的。我们的目的是在单中心环境中评估与BE和LGD/HGD患者RFA相关的安全性和有效性结果。方法:这是一项在丹麦Rigshospitalet外科和移植科进行的回顾性单中心研究。数据收集自2014年1月至2018年12月期间接受RFA治疗LGD或HGD的所有患者。疗效结果基于组织学:完全根除非典型增生(CE-D),定义为在最后一次活检时所有食管活检均为阴性;完全根除肠化生(CE-IM),定义为食管活检无肠化生。安全性结果基于RFA治疗并发症的比例。结果:随访期间共发现107例患者(75%为男性,中位年龄= 65岁);83%为LGD, 17%为HGD。中位随访时间为25个月。最后一次RFA治疗后,CE-D达到89%。CE-D和CE-IM达到60%。6.5%的患者出现并发症。结论:在BE和确诊的LGD或HGD患者中,RFA与高CE-D率和低并发症风险相关。观察到的安全性和有效性结果与先前在多中心试验中报道的结果相当,表明丹麦治疗合并LGD和HGD的BE与较大的欧洲专家中心相当。
{"title":"Radio frequency ablation of dysplastic Barrett's esophagus: Outcomes of a single-center registry.","authors":"Molly Mathiesen,&nbsp;Jakob Holm,&nbsp;Morten Thorsteinsson","doi":"10.1177/14574969231151378","DOIUrl":"https://doi.org/10.1177/14574969231151378","url":null,"abstract":"<p><strong>Background and objective: </strong>Barrett's esophagus (BE) is associated with an increased risk of esophageal adenocarcinoma. The use of radio frequency ablation (RFA) for complete eradication of BE with confirmed low-grade dysplasia (LGD) or high-grade dysplasia (HGD) has been promising in multicenter trials. Our aim was to evaluate the safety and efficacy outcomes associated with RFA for patients with BE and LGD/HGD in a single-center setting.</p><p><strong>Methods: </strong>This was a retrospective single-center study conducted at Department of Surgery and Transplantation, Rigshospitalet, Denmark. Data were collected from all patients who had undergone RFA for LGD or HGD from January 2014 to December 2018. Effectiveness outcomes were based on histology: complete eradication of dysplasia (CE-D), defined as all esophageal biopsies being negative for dysplasia at the last biopsy session, and complete eradication of intestinal metaplasia (CE-IM) defined as esophageal biopsies being without intestinal metaplasia. Safety outcomes were based on the proportion of complications to the RFA treatment.</p><p><strong>Results: </strong>A total of 107 patients were identified during the follow-up period (75% men, median age = 65 years); 83% had LGD and 17% had HGD. The median follow-up was 25 months. After the last RFA treatment, CE-D was achieved in 89%. CE-D and CE-IM were achieved in 60%. Complications occurred in 6.5% of the patients.</p><p><strong>Conclusions: </strong>In patients with BE and confirmed LGD or HGD, RFA was associated with a high rate of CE-D and a low risk of complications. The observed safety and efficacy outcomes were comparable with those previously reported in multicenter trials, showing that the Danish treatment of BE with LGD and HGD is comparable with those of larger European expert centers.</p>","PeriodicalId":49566,"journal":{"name":"Scandinavian Journal of Surgery","volume":"112 2","pages":"86-90"},"PeriodicalIF":2.4,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9694850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pancreatoduodenectomy after Roux-en-Y gastric bypass surgery: Single-center experience and literature review. Roux-en-Y胃旁路手术后胰十二指肠切除术:单中心经验和文献回顾。
IF 2.4 3区 医学 Q1 SURGERY Pub Date : 2023-06-01 Epub Date: 2023-02-21 DOI: 10.1177/14574969231156350
Sheraz Yaqub, Tore Tholfsen, Anne Waage, Dyre Kleive, Knut Jørgen Labori

Background and objective: Bariatric surgery with Roux-en-Y gastric bypass (RYGB) is widely used to treat morbid obesity and present diagnostic and therapeutic challenges in patients with pancreatic and periampullary tumors. The aim of this study was to describe diagnostic tools and challenges in performing pancreatoduodenectomy (PD) on patients with altered anatomy after RYGB.

Methods: Patients undergoing PD after RYGB from April 2015 to June 2022 at a tertiary referral center were identified. Preoperative workup, operative techniques, and outcomes were reviewed. A literature search was performed to identify articles reporting PD in post-RYGB patients.

Results: Of a total of 788 PDs, six patients had previous RYGB. The majority were women (n = 5), and median age was 59 years. The patients most commonly presented with pain (50%) and jaundice (50%) with a median of 5.5 years after RYGB. The gastric remnant was resected in all cases, and reconstruction of the pancreatobiliary drainage was achieved using the distal part of the pre-existing pancreatobiliary limb in all patients. Median follow-up was 60 months. The Clavien-Dindo grade ⩾3 complications occurred in two patients (33.3%), and 90 days mortality occurred in one patient (16.6%). The literature search revealed 9 articles reporting a total of 122 cases, specifically addressing PD after RYGB.

Conclusions: Reconstruction after PD in post-RYGB patients may be challenging. Resection of the gastric remnant and use of the pre-existing biliopancreatic limb may be a safe strategy, but surgeons should be prepared for other reconstruction options for creation of a new pancreatobiliary limb.

背景与目的:Roux-en-Y胃旁路手术(RYGB)被广泛应用于治疗病态肥胖,并对胰腺和壶腹周围肿瘤患者的诊断和治疗提出了挑战。本研究的目的是描述对RYGB后解剖结构改变的患者进行胰十二指肠切除术(PD)的诊断工具和挑战。方法:选取2015年4月至2022年6月在三级转诊中心接受RYGB后PD治疗的患者。回顾术前检查、手术技术和结果。进行文献检索,以确定报道rygb后患者PD的文章。结果:在总共788例pd中,6例患者既往有RYGB。大多数患者为女性(n = 5),中位年龄为59岁。患者最常见的症状是疼痛(50%)和黄疸(50%),中位时间为RYGB后5.5年。所有病例均切除残胃,所有患者均利用原有胰胆管肢体远端重建胰胆管引流。中位随访时间为60个月。Clavien-Dindo分级大于或小于3的并发症发生在两名患者中(33.3%),并且在一名患者中发生90天死亡率(16.6%)。文献检索显示9篇文章共报道122例病例,专门针对RYGB后PD。结论:rygb患者PD后重建可能具有挑战性。切除残胃和使用原有的胆道胰肢可能是一种安全的策略,但外科医生应该为其他重建选择做好准备,以创造新的胰胆肢。
{"title":"Pancreatoduodenectomy after Roux-en-Y gastric bypass surgery: Single-center experience and literature review.","authors":"Sheraz Yaqub, Tore Tholfsen, Anne Waage, Dyre Kleive, Knut Jørgen Labori","doi":"10.1177/14574969231156350","DOIUrl":"10.1177/14574969231156350","url":null,"abstract":"<p><strong>Background and objective: </strong>Bariatric surgery with Roux-en-Y gastric bypass (RYGB) is widely used to treat morbid obesity and present diagnostic and therapeutic challenges in patients with pancreatic and periampullary tumors. The aim of this study was to describe diagnostic tools and challenges in performing pancreatoduodenectomy (PD) on patients with altered anatomy after RYGB.</p><p><strong>Methods: </strong>Patients undergoing PD after RYGB from April 2015 to June 2022 at a tertiary referral center were identified. Preoperative workup, operative techniques, and outcomes were reviewed. A literature search was performed to identify articles reporting PD in post-RYGB patients.</p><p><strong>Results: </strong>Of a total of 788 PDs, six patients had previous RYGB. The majority were women (n = 5), and median age was 59 years. The patients most commonly presented with pain (50%) and jaundice (50%) with a median of 5.5 years after RYGB. The gastric remnant was resected in all cases, and reconstruction of the pancreatobiliary drainage was achieved using the distal part of the pre-existing pancreatobiliary limb in all patients. Median follow-up was 60 months. The Clavien-Dindo grade ⩾3 complications occurred in two patients (33.3%), and 90 days mortality occurred in one patient (16.6%). The literature search revealed 9 articles reporting a total of 122 cases, specifically addressing PD after RYGB.</p><p><strong>Conclusions: </strong>Reconstruction after PD in post-RYGB patients may be challenging. Resection of the gastric remnant and use of the pre-existing biliopancreatic limb may be a safe strategy, but surgeons should be prepared for other reconstruction options for creation of a new pancreatobiliary limb.</p>","PeriodicalId":49566,"journal":{"name":"Scandinavian Journal of Surgery","volume":"112 2","pages":"98-104"},"PeriodicalIF":2.4,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9696764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Operable colon cancer: New therapeutic perspectives, same old problems. 可手术结肠癌:新的治疗前景,同样的老问题。
IF 2.4 3区 医学 Q1 SURGERY Pub Date : 2023-06-01 DOI: 10.1177/14574969231181491
Andrea Morini, Maurizio Zizzo, Massimiliano Fabozzi
Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the Sage and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). Dear Editor,
{"title":"Operable colon cancer: New therapeutic perspectives, same old problems.","authors":"Andrea Morini,&nbsp;Maurizio Zizzo,&nbsp;Massimiliano Fabozzi","doi":"10.1177/14574969231181491","DOIUrl":"https://doi.org/10.1177/14574969231181491","url":null,"abstract":"Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the Sage and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). Dear Editor,","PeriodicalId":49566,"journal":{"name":"Scandinavian Journal of Surgery","volume":"112 2","pages":"135-136"},"PeriodicalIF":2.4,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9744884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Potential for intestinal transplantation after acute mesenteric ischemia in patients aged less than 70 years: A population-based study. 年龄小于70岁的患者急性肠系膜缺血后肠移植的潜力:一项基于人群的研究
IF 2.4 3区 医学 Q1 SURGERY Pub Date : 2023-06-01 DOI: 10.1177/14574969231151374
Aurora Lemma, Sampsa Pikkarainen, Anne Pohju, Matti Tolonen, Panu Mentula, Pirkka Vikatmaa, Ari Leppäniemi, Heikki Mäkisalo, Ville Sallinen

Background and objective: Acute mesenteric ischemia (AMI) has a high mortality rate due to the development of bowel necrosis. Patients are often ruled outside active care if a large proportion of small bowel is necrotic. With the development of treatment for short bowel syndrome (SBS) and intestinal transplantation methods, long-term survival is possible even after extensive small bowel resections. This study aims to assess the incidence of SBS and potentially suitable candidates for intestinal transplantation among patients treated for AMI.

Methods: This population-based retrospective study comprised patients aged less than 70 years and diagnosed with AMI between January 2006 and October 2020 in Helsinki and Uusimaa health care district, Finland.

Results: Altogether, AMI was diagnosed in 711 patients, of whom 133 (19%) were aged below 70. An intervention was performed in 110 (83%) patients. Of these 133 patients, 16 (12%) were ruled outside active treatment due to extensive small bowel necrosis at exploratory laparotomy, of whom 6 (5%) were potentially suitable for intestinal transplantation. Two patients were considered as potential candidates for intestinal transplantation at bowel resection but died of AMI. Nine (7%) patients needed parenteral nutrition after resection, and two of them (2%) developed SBS. Only one patient needed long-term parenteral nutrition after hospital discharge. This patient remained dependent on parenteral nutrition but died before evaluation of intestinal transplantation could be carried out while the other patient was able to return to enteral nutrition.

Conclusions: A small number of patients with AMI below 70 years of age are potentially eligible for intestinal transplantation.

背景与目的:急性肠系膜缺血(AMI)由于肠坏死的发展而具有很高的死亡率。如果大部分小肠坏死,患者通常不接受积极治疗。随着短肠综合征(SBS)治疗和肠道移植方法的发展,即使在广泛的小肠切除术后,长期生存也是可能的。本研究旨在评估急性心肌梗死患者中SBS的发生率和肠移植的潜在合适人选。方法:这项基于人群的回顾性研究纳入了2006年1月至2020年10月在芬兰赫尔辛基和Uusimaa卫生保健区诊断为AMI的年龄小于70岁的患者。结果:共有711例患者诊断为AMI,其中年龄在70岁以下的患者133例(19%)。110例(83%)患者接受了干预。在这133例患者中,16例(12%)由于剖腹探查时广泛的小肠坏死而被排除在积极治疗之外,其中6例(5%)可能适合肠移植。2例患者在肠切除术时被认为是肠移植的潜在候选者,但死于AMI。9例(7%)患者术后需要肠外营养,其中2例(2%)发生SBS。只有1例患者出院后需要长期肠外营养。该患者仍然依赖肠外营养,但在进行肠移植评估之前死亡,而另一名患者能够恢复肠内营养。结论:少数70岁以下AMI患者具有肠移植的潜在条件。
{"title":"Potential for intestinal transplantation after acute mesenteric ischemia in patients aged less than 70 years: A population-based study.","authors":"Aurora Lemma,&nbsp;Sampsa Pikkarainen,&nbsp;Anne Pohju,&nbsp;Matti Tolonen,&nbsp;Panu Mentula,&nbsp;Pirkka Vikatmaa,&nbsp;Ari Leppäniemi,&nbsp;Heikki Mäkisalo,&nbsp;Ville Sallinen","doi":"10.1177/14574969231151374","DOIUrl":"https://doi.org/10.1177/14574969231151374","url":null,"abstract":"<p><strong>Background and objective: </strong>Acute mesenteric ischemia (AMI) has a high mortality rate due to the development of bowel necrosis. Patients are often ruled outside active care if a large proportion of small bowel is necrotic. With the development of treatment for short bowel syndrome (SBS) and intestinal transplantation methods, long-term survival is possible even after extensive small bowel resections. This study aims to assess the incidence of SBS and potentially suitable candidates for intestinal transplantation among patients treated for AMI.</p><p><strong>Methods: </strong>This population-based retrospective study comprised patients aged less than 70 years and diagnosed with AMI between January 2006 and October 2020 in Helsinki and Uusimaa health care district, Finland.</p><p><strong>Results: </strong>Altogether, AMI was diagnosed in 711 patients, of whom 133 (19%) were aged below 70. An intervention was performed in 110 (83%) patients. Of these 133 patients, 16 (12%) were ruled outside active treatment due to extensive small bowel necrosis at exploratory laparotomy, of whom 6 (5%) were potentially suitable for intestinal transplantation. Two patients were considered as potential candidates for intestinal transplantation at bowel resection but died of AMI. Nine (7%) patients needed parenteral nutrition after resection, and two of them (2%) developed SBS. Only one patient needed long-term parenteral nutrition after hospital discharge. This patient remained dependent on parenteral nutrition but died before evaluation of intestinal transplantation could be carried out while the other patient was able to return to enteral nutrition.</p><p><strong>Conclusions: </strong>A small number of patients with AMI below 70 years of age are potentially eligible for intestinal transplantation.</p>","PeriodicalId":49566,"journal":{"name":"Scandinavian Journal of Surgery","volume":"112 2","pages":"77-85"},"PeriodicalIF":2.4,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9700608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prediction of postoperative pancreatic fistula and pancreatitis after pancreatoduodenectomy or distal pancreatectomy: A review. 胰十二指肠切除术或远端胰切除术后胰瘘和胰腺炎的预测:综述。
IF 2.4 3区 医学 Q1 SURGERY Pub Date : 2023-06-01 DOI: 10.1177/14574969231167781
Akseli Bonsdorff, Ville Sallinen

Background and objective: Postoperative pancreatic fistula (POPF) is the leading cause of morbidity and early mortality in patients undergoing pancreatic resection. In addition, recent studies have identified postoperative acute pancreatitis (POAP) as an independent contributor to morbidity. Most perioperative mitigation strategies experimented for POPF have been shown to be in vain with no consensus on the best perioperative management. Clinical prediction models have been developed with the hope of identifying high POPF risk patients with the leading idea of finding subpopulations possibly benefiting from pre-existing or novel mitigation strategies. The aim of this review was to map out the existing prediction modeling studies to better understand the current stage of POPF prediction modeling, and the methodology behind them.

Methods: A narrative review of the existing POPF prediction model studies was performed. Studies published before September 2022 were included.

Results: While the number of POPF prediction models for pancreatoduodenectomy has increased, none of the currently existing models stand out from the crowd. For distal pancreatectomy, two unique POPF prediction models exist, but due to their freshness, no further external validation or adoption in clinics or research has been reported. There seems to be a lack of adherence to correct methodology or reporting guidelines in most of the studies, which has rendered external validity-if assessed-low. Few of the most recent studies have demonstrated preoperative assessment of pancreatic aspects from computed tomography (CT) scans to provide relatively strong predictors of POPF.

Conclusions: Main goal for the future would be to reach a consensus on the most important POPF predictors and prediction model. At their current state, few models have demonstrated adequate transportability and generalizability to be up to the task. Better understanding of POPF pathophysiology and the possible driving force of acute inflammation and POAP might be required before such a prediction model can be accessed.

背景与目的:术后胰瘘(POPF)是胰腺切除术患者发病和早期死亡的主要原因。此外,最近的研究已经确定术后急性胰腺炎(POAP)是发病率的一个独立因素。大多数针对POPF的围手术期缓解策略已被证明是徒劳的,对于最佳围手术期管理没有达成共识。开发了临床预测模型,希望能够识别高POPF风险患者,并找到可能受益于现有或新的缓解策略的亚群。本综述的目的是梳理现有的预测建模研究,以更好地了解当前阶段的POPF预测建模及其背后的方法。方法:对现有的POPF预测模型研究进行叙述性回顾。纳入了2022年9月之前发表的研究。结果:虽然胰十二指肠切除术的POPF预测模型越来越多,但目前没有一个模型能脱颖而出。对于远端胰腺切除术,存在两种独特的POPF预测模型,但由于其新颖,没有进一步的外部验证或在临床或研究中采用的报道。在大多数研究中,似乎缺乏对正确方法或报告指南的遵守,这使得外部有效性(如果评估的话)很低。最近的一些研究表明,术前评估胰腺方面的计算机断层扫描(CT)扫描提供相对较强的预测POPF。结论:未来的主要目标是就最重要的POPF预测因子和预测模型达成共识。在它们目前的状态下,很少有模型显示出足够的可移植性和通用性来完成任务。在建立这样的预测模型之前,可能需要更好地了解POPF的病理生理以及急性炎症和POAP的可能驱动力。
{"title":"Prediction of postoperative pancreatic fistula and pancreatitis after pancreatoduodenectomy or distal pancreatectomy: A review.","authors":"Akseli Bonsdorff,&nbsp;Ville Sallinen","doi":"10.1177/14574969231167781","DOIUrl":"https://doi.org/10.1177/14574969231167781","url":null,"abstract":"<p><strong>Background and objective: </strong>Postoperative pancreatic fistula (POPF) is the leading cause of morbidity and early mortality in patients undergoing pancreatic resection. In addition, recent studies have identified postoperative acute pancreatitis (POAP) as an independent contributor to morbidity. Most perioperative mitigation strategies experimented for POPF have been shown to be in vain with no consensus on the best perioperative management. Clinical prediction models have been developed with the hope of identifying high POPF risk patients with the leading idea of finding subpopulations possibly benefiting from pre-existing or novel mitigation strategies. The aim of this review was to map out the existing prediction modeling studies to better understand the current stage of POPF prediction modeling, and the methodology behind them.</p><p><strong>Methods: </strong>A narrative review of the existing POPF prediction model studies was performed. Studies published before September 2022 were included.</p><p><strong>Results: </strong>While the number of POPF prediction models for pancreatoduodenectomy has increased, none of the currently existing models stand out from the crowd. For distal pancreatectomy, two unique POPF prediction models exist, but due to their freshness, no further external validation or adoption in clinics or research has been reported. There seems to be a lack of adherence to correct methodology or reporting guidelines in most of the studies, which has rendered external validity-if assessed-low. Few of the most recent studies have demonstrated preoperative assessment of pancreatic aspects from computed tomography (CT) scans to provide relatively strong predictors of POPF.</p><p><strong>Conclusions: </strong>Main goal for the future would be to reach a consensus on the most important POPF predictors and prediction model. At their current state, few models have demonstrated adequate transportability and generalizability to be up to the task. Better understanding of POPF pathophysiology and the possible driving force of acute inflammation and POAP might be required before such a prediction model can be accessed.</p>","PeriodicalId":49566,"journal":{"name":"Scandinavian Journal of Surgery","volume":"112 2","pages":"126-134"},"PeriodicalIF":2.4,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10073236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Management of urolithiasis in pregnancy: A systematic review and meta-analysis. 妊娠期尿石症的管理:一项系统回顾和荟萃分析。
IF 2.4 3区 医学 Q1 SURGERY Pub Date : 2023-06-01 DOI: 10.1177/14574969221145774
Hanieh Salehi-Pourmehr, Sona Tayebi, Nooriyeh DalirAkbari, Amir Ghabousian, Fateme Tahmasbi, Fatemeh Rahmati, Amirreza Naseri, Reyhaneh Hajebrahimi, Robab Mehdipour, Mahdi Hemmati-Ghavshough, Ali Mostafaei, Sakineh Hajebrahimi

Purpose: Management of nephrolithiasis is unique in pregnancy and requires multidisciplinary care. To identify the effectiveness or safety of temporary drainage or definitive treatment methods to manage urolithiasis in pregnancy.

Methods: The search strategy aimed to find both published and unpublished studies was conducted in August 2021. Studies published in any language on any date were considered for inclusion.

Results: Of a total of 3349 publications, 36 studies were included in our qualitative evaluation and 32 studies in the quantitative synthesis. The commonly reported method was stent insertion (n = 29 studies), pneumatic (n = 12), laser (n = 9) lithotripsy, and stone removal using any devices (basket, grasper, or forceps) (n = 11). In seven studies, the authors reported the outcomes of conservative management, and the results showed that the stone-free rate is 54%, and symptom relief occurred in 62% of women. Seven eligible studies reported that 79.9% of urolithiasis were expulsed through stent insertion, while this rate was 94.6% among percutaneous nephrostomy use in two included studies, 88.5% for pneumatic lithotripsy (n = 7 studies), and 76.4% for laser lithotripsy (n = 4 studies), or 95.4% for stone removal method. In addition, adverse events were reported in less than 10% of pregnant women.

Conclusions: The results showed that stent, pneumatic or laser lithotripsy, and ureteroscopic stone removal were the commonest used methods in the included studies. They can be effective and safe treatment approaches without major maternal or neonatal complications, and could be introduced as an effective and safe therapeutic method for urolithiasis during pregnancy. However, most of the included studies had moderate quality according to critical appraisal checklists. Further prospective studies are needed to reach a conclusion.

目的:肾结石的管理是独特的妊娠,需要多学科的护理。目的:探讨妊娠期尿石症临时引流或最终治疗方法的有效性和安全性。方法:检索策略旨在查找已发表和未发表的研究于2021年8月进行。在任何日期以任何语言发表的研究都被纳入考虑。结果:在总共3349篇文献中,我们的定性评价纳入了36篇,定量综合纳入了32篇。通常报道的方法是支架置入(n = 29),气压(n = 12),激光(n = 9)碎石,以及使用任何设备(篮子,抓握器或镊子)取出结石(n = 11)。在7项研究中,作者报告了保守治疗的结果,结果显示结石无结石率为54%,62%的女性出现症状缓解。7项符合条件的研究报告,79.9%的尿石症通过支架置入排出,其中两项纳入的研究中,经皮肾造口术的比例为94.6%,气动碎石术的比例为88.5% (n = 7项研究),激光碎石术的比例为76.4% (n = 4项研究),取石法的比例为95.4%。此外,不到10%的孕妇报告了不良事件。结论:结果显示,支架、气压或激光碎石、输尿管镜下取石是纳入研究中最常用的方法。它们是一种有效且安全的治疗方法,没有严重的孕产妇或新生儿并发症,可以作为妊娠期尿石症的一种有效且安全的治疗方法。然而,根据关键的评估清单,大多数纳入的研究质量中等。需要进一步的前瞻性研究来得出结论。
{"title":"Management of urolithiasis in pregnancy: A systematic review and meta-analysis.","authors":"Hanieh Salehi-Pourmehr,&nbsp;Sona Tayebi,&nbsp;Nooriyeh DalirAkbari,&nbsp;Amir Ghabousian,&nbsp;Fateme Tahmasbi,&nbsp;Fatemeh Rahmati,&nbsp;Amirreza Naseri,&nbsp;Reyhaneh Hajebrahimi,&nbsp;Robab Mehdipour,&nbsp;Mahdi Hemmati-Ghavshough,&nbsp;Ali Mostafaei,&nbsp;Sakineh Hajebrahimi","doi":"10.1177/14574969221145774","DOIUrl":"https://doi.org/10.1177/14574969221145774","url":null,"abstract":"<p><strong>Purpose: </strong>Management of nephrolithiasis is unique in pregnancy and requires multidisciplinary care. To identify the effectiveness or safety of temporary drainage or definitive treatment methods to manage urolithiasis in pregnancy.</p><p><strong>Methods: </strong>The search strategy aimed to find both published and unpublished studies was conducted in August 2021. Studies published in any language on any date were considered for inclusion.</p><p><strong>Results: </strong>Of a total of 3349 publications, 36 studies were included in our qualitative evaluation and 32 studies in the quantitative synthesis. The commonly reported method was stent insertion (<i>n</i> = 29 studies), pneumatic (<i>n</i> = 12), laser (<i>n</i> = 9) lithotripsy, and stone removal using any devices (basket, grasper, or forceps) (<i>n</i> = 11). In seven studies, the authors reported the outcomes of conservative management, and the results showed that the stone-free rate is 54%, and symptom relief occurred in 62% of women. Seven eligible studies reported that 79.9% of urolithiasis were expulsed through stent insertion, while this rate was 94.6% among percutaneous nephrostomy use in two included studies, 88.5% for pneumatic lithotripsy (<i>n</i> = 7 studies), and 76.4% for laser lithotripsy (<i>n</i> = 4 studies), or 95.4% for stone removal method. In addition, adverse events were reported in less than 10% of pregnant women.</p><p><strong>Conclusions: </strong>The results showed that stent, pneumatic or laser lithotripsy, and ureteroscopic stone removal were the commonest used methods in the included studies. They can be effective and safe treatment approaches without major maternal or neonatal complications, and could be introduced as an effective and safe therapeutic method for urolithiasis during pregnancy. However, most of the included studies had moderate quality according to critical appraisal checklists. Further prospective studies are needed to reach a conclusion.</p>","PeriodicalId":49566,"journal":{"name":"Scandinavian Journal of Surgery","volume":"112 2","pages":"105-116"},"PeriodicalIF":2.4,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10072726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Scandinavian Journal of Surgery
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1